Table 1.
Baseline patient characteristics.
| Characteristic | N = 30 |
|---|---|
| Age, years | |
| Mean (SD) | 62.0 (8.5) |
| Range (min, max) | 46, 79 |
| Sex, N (%) | |
| Male | 26 (87) |
| Female | 4 (13) |
| Race, N (%) | |
| White | 25 (83) |
| Black or African American | 3 (10) |
| Asian | 1 (3) |
| Other | 1 (3) |
| Ethnicity, N (%) | |
| Not Hispanic or Latino | 26 (87) |
| Hispanic or Latino | 4 (13) |
| Primary Tumor Site, N (%) | |
| Oral cavity | 11 (37) |
| Oropharynx (HPV-negative) | 8 (27) |
| Larynx | 4 (13) |
| Hypopharynx | 3 (10) |
| Nasopharynx (EBV-negative) | 1 (3) |
| Other | 3 (10) |
| ECOG Performance Status, N (%) | |
| 0 | 4 (13) |
| 1 | 26 (87) |
| Smoking status, N (%) | |
| Former | 16 (53) |
| Current | 7 (23) |
| Never | 7 (23) |
| Subjects with any prior radiotherapy, N (%) | 26 (87) |
| Subjects with any prior surgery, N (%) | 30 (100) |
| Number of prior systemic therapy regimens in the recurrent/metastatic setting, N (%) | |
| 1 | 0 |
| 2 | 1 (3) |
| 3 | 4 (13) |
| 4 | 6 (20) |
| ≥5 | 17 (57) |
| Unknown | 2 (17) |
| Prior systemic therapy, N (%) | |
| Cetuximab | 29 (97) |
| Pembrolizumab | 22 (73) |
| Carboplatin | 21 (70) |
| Cisplatin | 18 (60) |